Full Text View
Tabular View
Study Results
Related Studies
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)
This study has been completed.
Study NCT00513370   Information provided by Abbott
First Received: August 6, 2007   Last Updated: October 13, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriasis
More general conditions related to this trial
Skin Diseases
Skin Diseases, Papulosquamous
Interventions listed in this trial
Humira (adalimumab)
Additional drug interventions recognized in this trial
Adalimumab
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services